Jasper Hellweg
Stock Analyst at Argus Research
(2.11)
# 2,993
Out of 5,090 analysts
89
Total ratings
47.89%
Success rate
3.63%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BAX Baxter International | Downgrades: Hold | n/a | $18.54 | - | 3 | Oct 31, 2025 | |
| ZTS Zoetis | Reiterates: Buy | $190 | $118.65 | +60.13% | 7 | Sep 9, 2025 | |
| BIIB Biogen | Downgrades: Hold | n/a | $181.30 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $489.31 | -18.25% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $128.96 | +16.32% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $49.53 | +21.14% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $718.36 | +62.87% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $455.48 | +20.75% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $90.18 | -5.74% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $47.86 | +161.18% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $140 | $27.70 | +405.42% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $226.08 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $28.46 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $225.85 | +28.40% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $69.84 | +43.18% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $258.39 | +14.17% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.90 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $182.51 | -26.03% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $13.44 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $211.51 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $27.89 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $486.70 | -68.15% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $66.28 | +35.79% | 1 | Sep 19, 2018 |
Baxter International
Oct 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $18.54
Upside: -
Zoetis
Sep 9, 2025
Reiterates: Buy
Price Target: $190
Current: $118.65
Upside: +60.13%
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $181.30
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $489.31
Upside: -18.25%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $128.96
Upside: +16.32%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $49.53
Upside: +21.14%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $718.36
Upside: +62.87%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $455.48
Upside: +20.75%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $90.18
Upside: -5.74%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $47.86
Upside: +161.18%
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $27.70
Upside: +405.42%
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $226.08
Upside: -
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $28.46
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $225.85
Upside: +28.40%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $69.84
Upside: +43.18%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $258.39
Upside: +14.17%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $11.90
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $182.51
Upside: -26.03%
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $13.44
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $211.51
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $27.89
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $486.70
Upside: -68.15%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $66.28
Upside: +35.79%